MedTrace Logo

Allogeinic Bone Paste

NCT04605120 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-10-27

No results posted yet for this study

Summary

This is a prospective, single arm, single center clinical study to evaluate efficacy and safety of a Supercritical CO2 viral-inactivated allogenic bone paste in cervical interbody fusion. Patient eligible for 1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft after failure of well-conducted medical treatment will be screened for the study.

Conditions

  • Cervical Fusion
  • Cervical Disc Degeneration
  • Spinal Fusion

Interventions

PROCEDURE

Cervical fusion

1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft

Sponsors & Collaborators

  • Biobank

    lead INDUSTRY

Principal Investigators

  • Jean-Charles LE HUEC, M.D., Prof · Polyclinique Bordeaux Nord Aquitaine - BORDEAUX - FRANCE

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2023-06-30
Completion
2023-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04605120 on ClinicalTrials.gov